Dr Gossec et al. Multidomain indices show consistent benefit when applied to IL23i guselkumab COSMOS trial. I like MDA (because its simple and so am I) so showing that. But same benefits seen in DAPSA, PASDAS, mCPDAI, GRACE, PsARC. @RheumNow #EULAR2022 POS1038 https://t.co/EU2VHpEGc3